XML 101 R95.htm IDEA: XBRL DOCUMENT v3.26.1
Reportable Segment Information - Summary of Financial Information for Each Reportable Segment (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2026
Mar. 31, 2025
Sep. 30, 2025
Segment Reporting Information [Line Items]          
Sales $ 482 $ 479 $ 868 $ 884  
Cost of sales 335 332 616 626  
Selling, general and administrative expense 79 85 165 162  
Research and development expense 14 14 27 28  
Equity and other income 0 0 1 1  
Income (loss) on divestitures, net 0 18 2 (165)  
Operating income (loss) 39 51 33 (128)  
Net interest and other expense 18 11 26 39  
Other net periodic benefit loss 1 1 2 3  
Income (loss) from continuing operations before income taxes 20 39 5 (170)  
EBITDA [1] 84 111 126 (17)  
Depreciation expense 30 45 63 79  
Amortization expense 15 15 30 32  
Assets 4,499   4,499   $ 4,611
Property, plant and equipment, net 1,163   1,163   1,201
Operating Segments [Member]          
Segment Reporting Information [Line Items]          
Selling, general and administrative expense 60 56 119 116  
Research and development expense 13 14 25 26  
Equity and other income 0 0 1 1  
Income (loss) on divestitures, net 0 0 0 0  
Operating income (loss) 59 62 79 85  
EBITDA [1] 104 122 172 196  
Depreciation expense 30 45 63 79  
Amortization expense 15 15 30 32  
Intersegment Eliminations [Member]          
Segment Reporting Information [Line Items]          
Sales [2] (9) (10) (18) (21)  
Cost of sales (9) (10) (18) (21)  
Life Sciences [Member]          
Segment Reporting Information [Line Items]          
Sales 172 172 311 306  
Assets 1,455   1,455   1,498
Property, plant and equipment, net 468   468   481
Life Sciences [Member] | Operating Segments [Member]          
Segment Reporting Information [Line Items]          
Sales 172 172 311 306  
Cost of sales 109 117 203 208  
Selling, general and administrative expense 20 19 40 40  
Research and development expense 3 4 7 8  
Equity and other income 0 0 0 0  
Income (loss) on divestitures, net 0 0 0 0  
Operating income (loss) 35 28 52 42  
EBITDA [1] 49 54 80 81  
Depreciation expense [3] 9 22 19 31  
Amortization expense 5 4 9 8  
Personal Care [Member]          
Segment Reporting Information [Line Items]          
Assets 714   714   751
Property, plant and equipment, net 95   95   101
Personal Care [Member] | Operating Segments [Member]          
Segment Reporting Information [Line Items]          
Sales 150 146 273 279  
Cost of sales 88 82 167 169  
Selling, general and administrative expense 21 21 42 41  
Research and development expense 6 7 11 12  
Equity and other income 0 0 1 1  
Income (loss) on divestitures, net 0 0 0 0  
Operating income (loss) 27 28 38 39  
EBITDA [1] 42 43 68 73  
Depreciation expense 7 7 14 15  
Amortization expense 8 8 16 19  
Specialty Additives [Member]          
Segment Reporting Information [Line Items]          
Sales 134 134 236 249  
Assets 988   988   1,020
Property, plant and equipment, net 468   468   484
Specialty Additives [Member] | Operating Segments [Member]          
Segment Reporting Information [Line Items]          
Sales 134 134 236 249  
Cost of sales 118 106 206 205  
Selling, general and administrative expense 17 15 33 31  
Research and development expense 4 3 7 6  
Equity and other income 0 0 0 0  
Income (loss) on divestitures, net 0 0 0 0  
Operating income (loss) (7) 7 (15) 2  
EBITDA [1] 8 23 18 34  
Depreciation expense [4] 13 13 28 27  
Amortization expense 2 3 5 5  
Intermediates [Member]          
Segment Reporting Information [Line Items]          
Assets 107   107   116
Property, plant and equipment, net 30   30   30
Intermediates [Member] | Operating Segments [Member]          
Segment Reporting Information [Line Items]          
Sales 35 37 66 71  
Cost of sales 29 37 58 65  
Selling, general and administrative expense 2 1 4 4  
Research and development expense 0 0 0 0  
Equity and other income 0 0 0 0  
Income (loss) on divestitures, net 0 0 0 0  
Operating income (loss) 4 (1) 4 2  
EBITDA [1] 5 2 6 8  
Depreciation expense 1 3 2 6  
Amortization expense 0 0 0 0  
Unallocated and Other [Member]          
Segment Reporting Information [Line Items]          
Selling, general and administrative expense 19 29 46 46  
Research and development expense 1 0 2 2  
Equity and other income 0 0 0 0  
Income (loss) on divestitures, net (0) 18 2 (165)  
Operating income (loss) [5] (20) (11) (46) (213)  
EBITDA [1] (20) (11) (46) (213)  
Depreciation expense 0 0 0 0  
Amortization expense 0 $ 0 0 $ 0  
Assets 1,235   1,235   1,226
Property, plant and equipment, net $ 102   $ 102   $ 105
[1] Excludes income from discontinued operations, net of income taxes and other net periodic benefit loss. See the Statements of Condensed Consolidated Comprehensive Income (Loss) for applicable amounts excluded.
[2] Intersegment sales from Intermediates are accounted for at prices that approximate market value. All other intersegment sales are accounted for at cost.
[3] Depreciation includes accelerated depreciation of $13 million for Life Sciences for both the three and six months ended March 31, 2025.
[4] Depreciation includes accelerated depreciation of $3 million for Specialty Additives for the six months ended March 31, 2026.
[5] Includes a $2 million gain on sale of excess corporate property for the six months ended March 31, 2026, a $8 million gain on sale of excess corporate property for both the three and six months ended March 31, 2025, and a $183 million impairment charge related to the Avoca business for the six months ended March 31, 2025, within the income (loss) on divestitures, net caption of the Statements of Condensed Consolidated Income (Loss).